Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for ImmunityBio (IBRX) over the last 10 years, with Q3 2025 value amounting to $115.2 million.

  • ImmunityBio's Other Non-Current Liabilities rose 49907.4% to $115.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.2 million, marking a year-over-year increase of 49907.4%. This contributed to the annual value of $26.1 million for FY2024, which is 7800.79% down from last year.
  • ImmunityBio's Other Non-Current Liabilities amounted to $115.2 million in Q3 2025, which was up 49907.4% from $67.0 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Other Non-Current Liabilities peaked at $118.8 million during Q4 2023, and registered a low of $288000.0 during Q1 2022.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $20.5 million (2025), whereas its average is $34.4 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 948586.21% in 2023, then crashed by 8132.32% in 2025.
  • Quarter analysis of 5 years shows ImmunityBio's Other Non-Current Liabilities stood at $411000.0 in 2021, then soared by 5164.23% to $21.6 million in 2022, then surged by 448.95% to $118.8 million in 2023, then tumbled by 78.01% to $26.1 million in 2024, then skyrocketed by 340.89% to $115.2 million in 2025.
  • Its last three reported values are $115.2 million in Q3 2025, $67.0 million for Q2 2025, and $20.5 million during Q1 2025.